Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Riccetti, Nicola; Blettner, Maria; Taylor, Katherine et al.
Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARISJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 148. H. 8. 2022 S. 1943-1953
Bostel, T.; Akbaba, S.; Mayer, A. et al.
Radiation Therapy in geriatric Patients with Adenocarcinoma of the Esophagus or gastroesophageal Junction: Multi-centre Analysis of the Importance of Standard Care in the elderly PeopleSTRAHLENTHERAPIE UND ONKOLOGIE. Bd. 198. H. SUPPL 1. 2022 S. S112-S113
Bostel, T.; Bostel, T.; Akbaba, S. et al.
Radiation Therapy in geriatric Patients with Esophageal Squamous Cell Carcinoma: Multicenter Analysis of the Importance of Care Standard in the elderly PeopleSTRAHLENTHERAPIE UND ONKOLOGIE. Bd. 198. H. SUPPL 1. 2022 S. S110-S111
Grandt, Caine Lucas; Brackmann, Lara Kim; Poplawski, Alicia et al.
Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme studyMOLECULAR MEDICINE. Bd. 28. H. 1. 2022
Stoehr, Fabian; Kloeckner, Roman; Dos Santos, Daniel Pinto et al.
Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC-A Proof-of-Concept StudyCANCERS. Bd. 14. H. 24. 2022
Harter, Philipp; Sehouli, Jalid; Vergote, Ignace et al.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer (vol 385, pg 2123, 2021)NEW ENGLAND JOURNAL OF MEDICINE. Bd. 386. H. 7. 2022 S. 704-704
Achajew, Aisana; Brecht, Ines B.; Radespiel-Troeger, Martin et al.
Rare pediatric tumors in Germany - not as rare as expected: a study based on data from the Bavarian Cancer Registry and the German Childhood Cancer RegistryEUROPEAN JOURNAL OF PEDIATRICS. Bd. 181. H. 7. 2022 S. 2723-2730
Lueftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 16. 2022
Luftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA studyCANCER RESEARCH. Bd. 82. H. 4. 2022
Hess, Georg; Dreyling, Martin; Oberic, Lucie et al.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyBRITISH JOURNAL OF HAEMATOLOGY. 2022